An Update on Iowa’s Medical Cannabidiol Program
For questions about registration, please contact Iowa State University by email or phone 515-294-6222.
For questions about program content, please email Kayla Sankey.
For more information on IDPH’s initiatives, please visit YourLifeIowa.org.
More From The Virtual Learning Series
August 13 Contingency Management: A First Line Intervention for Treatment of Stimulant Use Disorders
August 26 The New Nicotine Addiction
September 2 Certified Community Behavioral Health Clinics: Improving Care and Outcomes for Individuals with Substance Use Disorders
September 15 Alcohol-Related Disparities in Iowa: What We Know and What We Can Do
September 16 Telehealth in Iowa
The target audience for these trainings are community service providers and health professionals who would benefit from behavioral health education.
Develop an understanding of the challenges, structure, and data from the first 18 months of Iowa’s program, and how the passage of HF2589 makes changes to the program.
- Discuss the challenges, stakeholders, regulatory structure, and program data leading up to the passage of HF2589.
- Recognize how HF2589 expands Iowa’s Medical Cannabidiol Program.
Owen Parker, MPH
Program Manager, Office of Medical Cannabidiol, Iowa Department of Public Health
Mr. Parker has served as the Program Manager for the Office of Medical Cannabidiol for over two years developing and implementing Iowa’s program. Owen received his Master of Public Health degree from the University of Iowa, and his Biology degree and minor in chemistry from the University of Northern Iowa. He has been working on the regulatory side of cannabis in other states since 2015.
Mr. Parker indicates that he has no financial relationships with commercial interest companies to disclose relevant to the content of this educational activity.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 1.25 continuing education contact hour(s). No partial credit awarded.
No commercial interest provided financial support for this continuing education activity.
Everyone in a position to control the content of this educational activity will disclose to the CME provider and to attendees all relevant financial relationships with any commercial interest. The speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
The information shared at this event is presented as an opportunity to expand awareness and knowledge. Views expressed by speakers do not represent the views of the Iowa Department of Public Health, nor does IDPH control or guarantee the accuracy of this information. IDPH does not endorse individual vendors, products or services.
- 1.25 IBON